eClinical Tech News

Kyverna outlined a registrational path for KYV-101 in generalized myasthenia gravis (MG), converting its KYSA-6 study into a Phase...

In its pivotal Phase 3 study, arimoclomol (MIPLYFFA) halted disease progression versus placebo over 12 months on the NPC...

No new efficacy or safety numbers were disclosed. Still, AAVantgarde Bio will present updated Phase 1/2 LUCE-1 data for...

Anavex Life Sciences has published preclinical data in •iScience• further elucidating the mechanism by which its SIGMAR1 (S1R) agonist,...

Incannex Healthcare’s Phase 2 trial of PSX-001 (formerly Psi-GAD), a psilocybin-assisted therapy for generalized anxiety disorder (GAD), demonstrated statistically...

Cemdisiran monotherapy, administered subcutaneously every three months, demonstrated a 2.3-point placebo-adjusted improvement in the Myasthenia Gravis Activities of Daily...

BioXcel Therapeutics’ BXCL501, a sublingual dexmedetomidine film, met its primary endpoint of tolerability in the SERENITY At-Home Phase 3...

Life Biosciences’ preclinical data from the ARDD meeting showcase promising results for its Partial Epigenetic Reprogramming (PER) platform in...

Oryzon Genomics has received EMA approval for a Phase 1b trial of iadademstat in sickle cellsickle cell disease (SCD)....

Artelo Biosciences announced positive safety and pharmacokinetic data from a Phase 1 single-ascending-dose (SAD) trial, including a preliminary food...